Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo

Mol Cancer Ther (2019) 18 (4): 733–742.

https://doi.org/10.1158/1535-7163.MCT-18-1085

Published: 01 April 2019

View article titled, TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Includes: Supplementary data

Journal Articles

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

Wakako Yano, Tatsushi Yokogawa, Takeshi Wakasa, Keisuke Yamamura, Akio Fujioka, Kunihiro Yoshisue, Eiji Matsushima, Seiji Miyahara, Hitoshi Miyakoshi, Junko Taguchi, Khoon Tee Chong, Yayoi Takao, Masayoshi Fukuoka, Kenichi Matsuo

Mol Cancer Ther (2018) 17 (8): 1683–1693.

https://doi.org/10.1158/1535-7163.MCT-17-0911

Published: 31 July 2018

View article titled, TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

Includes: Supplementary data

Journal Articles

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Hiroki Irie, Kei Oguchi, Kimihiro Ito, Yayoi Fujioka, Yuichi Kawai, Tadashi Shimamura, Hikari Araki, Akio Fujioka, Fumio Nakagawa, Rumi Kawabata, Hideki Nagase, Takeshi Sagara, Junji Uchida, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa

Mol Cancer Ther (2018) 17 (1_Supplement): B179.

https://doi.org/10.1158/1535-7163.TARG-17-B179

Published: 01 January 2018

View article titled, Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Journal Articles

Abstract B88: TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC.

Wakako Yano, Sayaka Tsukioka, Tatsushi Yokogawa, Satoko Ito, Keiji Ishida, Keisuke Yamamura, Akio Fujioka, Masayoshi Fukuoka, Kenichi Matsuo, Kazuharu Noguchi, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): B88.

https://doi.org/10.1158/1535-7163.TARG-13-B88

Published: 01 November 2013

View article titled, Abstract B88: TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC.

Journal Articles

Abstract B89: Expression of DNA damage repair enzymes determine the efficacy of a novel dUTPase inhibitor, TAS-114.

Sayaka Tsukioka, Wakako Yano, Tatsushi Yokogawa, Takeshi Wakasa, Akio Fujioka, Keisuke Yamamura, Satoko Itoh, Masayoshi Fukuoka, Kenichi Matsuo, Kazuharu Noguchi, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): B89.

https://doi.org/10.1158/1535-7163.TARG-13-B89

Published: 01 November 2013

View article titled, Abstract B89: Expression of DNA damage repair enzymes determine the efficacy of a novel dUTPase inhibitor, TAS-114.

Journal Articles

Abstract B86: Potent antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, on both cetuximab-sensitive KRAS wild-type and cetuximab-resistant KRAS mutated colorectal cancer cells via trifluorothymidine incorporation into DNA.

Nozomu Tanaka, Yukari Yamada, Akio Fujioka, Keisuke Yamamura, Satoko Ito, Kenichi Matsuo, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): B86.

https://doi.org/10.1158/1535-7163.TARG-13-B86

Published: 01 November 2013

View article titled, Abstract B86: Potent antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, on both cetuximab-sensitive <em>KRAS</em> wild-type and cetuximab-resistant <em>KRAS</em> mutated colorectal cancer cells via trifluorothymidine incorporation into DNA.

Journal Articles

Abstract B87: Preclinical investigation of the potentiation in antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, in combination with irinotecan (CPT-11) in colorectal cancer.

Keiji Ishida, Nozomu Tanaka, Sayaka Tsukioka, Kokoro Eshima, Akio Fujioka, Keisuke Yamamura, Satoko Ito, Kenichi Matsuo, Teruhiro Utsugi

Mol Cancer Ther (2013) 12 (11_Supplement): B87.

https://doi.org/10.1158/1535-7163.TARG-13-B87

Published: 01 November 2013

View article titled, Abstract B87: Preclinical investigation of the potentiation in antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, in combination with irinotecan (CPT-11) in colorectal cancer.

NARROW

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Abstract B88: TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC.

Abstract B89: Expression of DNA damage repair enzymes determine the efficacy of a novel dUTPase inhibitor, TAS-114.

Abstract B86: Potent antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, on both cetuximab-sensitive KRAS wild-type and cetuximab-resistant KRAS mutated colorectal cancer cells via trifluorothymidine incorporation into DNA.

Abstract B87: Preclinical investigation of the potentiation in antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, in combination with irinotecan (CPT-11) in colorectal cancer.

Email alerts

AACR Journals

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Abstract B88: TAS-114, a dUTPase inhibitor, in combination with pemetrexed is a novel strategy for the treatment of NSCLC.

Abstract B89: Expression of DNA damage repair enzymes determine the efficacy of a novel dUTPase inhibitor, TAS-114.

Abstract B86: Potent antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, on both cetuximab-sensitive KRAS wild-type and cetuximab-resistant KRAS mutated colorectal cancer cells via trifluorothymidine incorporation into DNA.

Abstract B87: Preclinical investigation of the potentiation in antitumor effect of TAS-102, a novel oral anti-neoplastic nucleoside agent, in combination with irinotecan (CPT-11) in colorectal cancer.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only